Baidu
map

检验

订阅

MedSci主页 / 所有栏目 / 检验

JCLA：Mindray CAL 8000（BC-6800和SC-120）血液分析仪和slidemaker/stainer的性能评估

2017-07-24 MedSci MedSci原创

血细胞分析仪性能评估
关注

迈瑞CAL 8000是一种细胞分析系统，由BC-6800（自动血液分析仪）和SC-120（slidemaker/stainer）组成。本项研究评估了BC-6800和SC-120的性能。研究分析了488个正常和病例样本。比较BC-6800和Sysmex XE-2100的性能，并根据CLSI指南H26-A2和H20-A2对SC-120和手动方法的血液膜进行了比较。

近日，国际杂志 《Journal of Clinical Laboratory Analysis》上在线发表一项关于Mindray CAL 8000（BC-6800和SC-120）血液分析仪和slidemaker/stainer的性能评估的研究。

迈瑞CAL 8000是一种细胞分析系统，由BC-6800（自动血液分析仪）和SC-120（slidemaker/stainer）组成。本项研究评估了BC-6800和SC-120的性能。研究分析了488个正常和病例样本。比较BC-6800和Sysmex XE-2100的性能，并根据CLSI指南H26-A2和H20-A2对SC-120和手动方法的血液膜进行了比较。

BC-6800测量的大多数参数与XE-2100和手动差速器一致。BC-6800对原细胞（95.3％）和非典型淋巴细胞（92.6％）的标记效率较高，而未成熟粒细胞（89.7％）和NRBC（94.1％）均低于XE-2100。此外，BC-6800检测到5个感染疟原虫寄生虫的样本中的4个。SC-120没有结转和达到预期的重复性。对于包括SC-120和手工制备的血膜的血膜之间的异常细胞的五部分有很好的一致性。红血球的形状在血膜之间也差不多。

研究表明，CAL-8000分析线有助于精确，快速的血液检测工作，在疟疾流行地区可能更能够显示其优势。


原始出处：

Hwan Tae Lee, Pil-Whan Park, Yiel-Hea Seo, et.al. Performance evaluation of Mindray CAL 8000(BC-6800 and SC-120) hematology analyzer and slidemaker/stainer.

本文系梅斯医学（MedSci）原创编译整理，转载需授权！


版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1936574, encodeId=91e919365e48a, content=<a href='/topic/show?id=ef0989249d3' target=_blank style='color:#2F92EE;'>#血液分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89249, encryptionId=ef0989249d3, topicName=血液分析)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Sat Apr 28 00:59:00 CST 2018, time=2018-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1988545, encodeId=f75319885453b, content=<a href='/topic/show?id=9bde52e0831' target=_blank style='color:#2F92EE;'>#性能评估#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52708, encryptionId=9bde52e0831, topicName=性能评估)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Sat Dec 16 05:59:00 CST 2017, time=2017-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317334, encodeId=a3d6131e33465, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Wed Jul 26 06:59:00 CST 2017, time=2017-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469089, encodeId=225214690890e, content=<a href='/topic/show?id=211f98250b' target=_blank style='color:#2F92EE;'>#IND#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9825, encryptionId=211f98250b, topicName=IND)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=16377007930, createdName=xiaogang319, createdTime=Wed Jul 26 06:59:00 CST 2017, time=2017-07-26, status=1, ipAttribution=)]
    2018-04-28 ms5353107019656438

    #血液分析#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1936574, encodeId=91e919365e48a, content=<a href='/topic/show?id=ef0989249d3' target=_blank style='color:#2F92EE;'>#血液分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89249, encryptionId=ef0989249d3, topicName=血液分析)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Sat Apr 28 00:59:00 CST 2018, time=2018-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1988545, encodeId=f75319885453b, content=<a href='/topic/show?id=9bde52e0831' target=_blank style='color:#2F92EE;'>#性能评估#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52708, encryptionId=9bde52e0831, topicName=性能评估)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Sat Dec 16 05:59:00 CST 2017, time=2017-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317334, encodeId=a3d6131e33465, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Wed Jul 26 06:59:00 CST 2017, time=2017-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469089, encodeId=225214690890e, content=<a href='/topic/show?id=211f98250b' target=_blank style='color:#2F92EE;'>#IND#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9825, encryptionId=211f98250b, topicName=IND)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=16377007930, createdName=xiaogang319, createdTime=Wed Jul 26 06:59:00 CST 2017, time=2017-07-26, status=1, ipAttribution=)]
    2017-12-16 luoxiaog

    #性能评估#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1936574, encodeId=91e919365e48a, content=<a href='/topic/show?id=ef0989249d3' target=_blank style='color:#2F92EE;'>#血液分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89249, encryptionId=ef0989249d3, topicName=血液分析)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Sat Apr 28 00:59:00 CST 2018, time=2018-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1988545, encodeId=f75319885453b, content=<a href='/topic/show?id=9bde52e0831' target=_blank style='color:#2F92EE;'>#性能评估#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52708, encryptionId=9bde52e0831, topicName=性能评估)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Sat Dec 16 05:59:00 CST 2017, time=2017-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317334, encodeId=a3d6131e33465, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Wed Jul 26 06:59:00 CST 2017, time=2017-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469089, encodeId=225214690890e, content=<a href='/topic/show?id=211f98250b' target=_blank style='color:#2F92EE;'>#IND#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9825, encryptionId=211f98250b, topicName=IND)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=16377007930, createdName=xiaogang319, createdTime=Wed Jul 26 06:59:00 CST 2017, time=2017-07-26, status=1, ipAttribution=)]
    2017-07-26 fengyi812

    #EMA#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1936574, encodeId=91e919365e48a, content=<a href='/topic/show?id=ef0989249d3' target=_blank style='color:#2F92EE;'>#血液分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89249, encryptionId=ef0989249d3, topicName=血液分析)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Sat Apr 28 00:59:00 CST 2018, time=2018-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1988545, encodeId=f75319885453b, content=<a href='/topic/show?id=9bde52e0831' target=_blank style='color:#2F92EE;'>#性能评估#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52708, encryptionId=9bde52e0831, topicName=性能评估)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Sat Dec 16 05:59:00 CST 2017, time=2017-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317334, encodeId=a3d6131e33465, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Wed Jul 26 06:59:00 CST 2017, time=2017-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469089, encodeId=225214690890e, content=<a href='/topic/show?id=211f98250b' target=_blank style='color:#2F92EE;'>#IND#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9825, encryptionId=211f98250b, topicName=IND)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=16377007930, createdName=xiaogang319, createdTime=Wed Jul 26 06:59:00 CST 2017, time=2017-07-26, status=1, ipAttribution=)]
    2017-07-26 xiaogang319

    #IND#

    0

Baidu
map
Baidu
map
Baidu
map